Available online at www.sciencedirect.com
SCIENCE DIRECT®
ELSEVIER
Diabetes Research and Clinical Practice 61 (2003) 211–213
DIABETES RESEARCH AND CLINICAL PRACTICE
www.elsevier.com/locate/diabres

Author index of volume 61

Afrashi, F., T. Erakgün, S. Köse, K. Ardıç, J. Menteş, Blue-on-yellow perimetry versus achromatic perimetry in type 1 diabetes patients without retinopathy **61**, 7
Airaksinen, K.E.J., see Vikman, S. **61**, 39
Akçay, T., Y. Dinçer, N. Çelebi, H. İlkova, O^6-methylguanine DNA methyltransferase activity in diabetic patients **61**, 1
Almeida, O.P., see Bruce, D.G. **61**, 59
Ardıç, K., see Afrashi, F. **61**, 7
Asada, M., see Ogawa, D. **61**, 137
Asai, M., T. Kodera, K. Ishizeki, S. Uebori, T. Kashiwaya, H. Itoh, I. Makino, Insulin lispro reduces insulin antibodies in a patient with type 2 diabetes with immunological insulin resistance **61**, 89
Asakawa, H., I. Hayashi, T. Fukui, K. Tokunaga, Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy **61**, 175
Azizi, F., P. Salehi, A. Etemadi, S. Zahedi-Asl, Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study **61**, 29

Bell, P.M., see Lindsay, J.R. **61**, 167
Bhonde, R.R., Human pancreatic β-cells have potential to regenerate in vivo **61**, 78
Blaak, E.E., see Mensink, M. **61**, 49
Bruce, D.G., G.P. Casey, V. Grange, R.C. Clarnette, O.P. Almeida, J.K. Foster, F.J. Ives, T.M.E. Davis, Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study **61**, 59

Casey, G.P., see Bruce, D.G. **61**, 59
Çelebi, N., see Akçay, T. **61**, 1
Chen, J.-W., see Pan, C.-Y. **61**, 183
Cheng, H., see Pan, C.-Y. **61**, 183
Cho, N.H., see Jang, H.C. **61**, 117
Clarnette, R.C., see Bruce, D.G. **61**, 59
Corpeleijn, E., see Mensink, M. **61**, 49
Costa-e-Forti, A., see Nascimento, N.R.F. **61**, 145
Crosby, R.D., see Kolotkin, R.L. **61**, 125

Davis, T.M.E., see Bruce, D.G. **61**, 59
de Bruin, T.W.A., see Mensink, M. **61**, 49
Dinçer, Y., see Akçay, T. **61**, 1

El Fakiri, F., M. Foets, M. Rijken, Health care use by diabetic patients in the Netherlands: patterns and predicting factors **61**, 199
Emoto, M., see Yokoyama, H. **61**, 161
Erakgün, T., see Afrashi, F. **61**, 7
Etemadi, A., see Azizi, F. **61**, 29

Fernandes, T.J., see Halfoun, V.L.R.C. **61**, 155
Feskens, E.J.M., see Mensink, M. **61**, 49
Flatt, P.R., see Lindsay, J.R. **61**, 167
Foets, M., see El Fakiri, F. **61**, 199
Fonteles, M.C., see Nascimento, N.R.F. **61**, 145
Foster, J.K., see Bruce, D.G. **61**, 59
Fu, Z.-Z., see Pan, C.-Y. **61**, 183
Fujii, Y., see Ochi, M. **61**, 191
Fujinami, A., see Nakamura, N. **61**, 93
Fukui, T., see Asakawa, H. **61**, 175
Fukumoto, S., see Yokoyama, H. **61**, 161
Furukawa, F., see Shimomura, H. **61**, 103
Furuta, H., see Shimomura, H. **61**, 103

Gao, Y., see Pan, C.-Y. **61**, 183
Grange, V., see Bruce, D.G. **61**, 59
Guo, X.-H., see Pan, C.-Y. **61**, 183
Gupta, A., R. Gupta, M. Sarna, S. Rastogi, V.P. Gupta, K. Kothari, Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population **61**, 69
Gupta, R., see Gupta, A. **61**, 69
Gupta, V.P., see Gupta, A. **61**, 69

Halfoun, V.L.R.C., M.L.E. Pires, T.J. Fernandes, F. Victer, K.K. Rodrigues, R. Tavares, Videocapillaroscopy and Diabetes mellitus: area of transverse segment in nailfold capillar loops reflects vascular reactivity **61**, 155
Han, I.-K., see Jang, H.C. **61**, 117
Han, K.O., see Jang, H.C. **61**, 117
Hanabusa, T., see Shimomura, H. **61**, 103
Hasegawa, G., see Nakamura, N. **61**, 93
Hayashi, I., see Asakawa, H. **61**, 175
Hu, Y.M., H.M. Tian, R. Liu, Gln–Arg192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese **61**, 21

Ikeda, T., see Nakamura, N. **61**, 93

doi:10.1016/S0168-8227(03)00199-2

İlkova, H., see Akçay, T. **61**, 1
Ilva, T., see Vikman, S. **61**, 39
Imamura, Y., see Nakamura, N. **61**, 93
Inouye, M., see Miwa, S. **61**, 81
Ishizeki, K., see Asai, M. **61**, 89
Itoh, H., see Asai, M. **61**, 89
Ives, F.J., see Bruce, D.G. **61**, 59

Jang, H.C., C.-H. Yim, K.O. Han, H.-K. Yoon, I.-K. Han, M.-Y. Kim, J.-H. Yang, N.H. Cho, Gestational diabetes mellitus in Korea: prevalence and prediction of glucose intolerance at early postpartum **61**, 117

Kamei, N., see Nakanishi, S. **61**, 109
Kashiwaya, T., see Asai, M. **61**, 89
Kato, K., see Ochi, M. **61**, 191
Kawamori, R., see Miwa, S. **61**, 81
Kim, M.-Y., see Jang, H.C. **61**, 117
Kinoshita, S., see Nakamura, N. **61**, 93
Kitagawa, Y., see Yokoyama, H. **61**, 161
Klingler, A., see Weitgasser, R. **61**, 13
Kodera, T., see Asai, M. **61**, 89
Kohno, N., see Nakanishi, S. **61**, 109
Kolotkin, R.L., R.D. Crosby, G.R. Williams, Assessing weight-related quality of life in obese persons with type 2 diabetes **61**, 125
Köse, S., see Afrashi, F. **61**, 7
Kothari, K., see Gupta, A. **61**, 69
Koyama, H., see Yokoyama, H. **61**, 161
Kruijshoop, M., see Mensink, M. **61**, 49

Lechleitner, M., see Weitgasser, R. **61**, 13
Lindsay, J.R., A.M. McKillop, M.H. Mooney, F.P.M. O'Harte, P.R. Flatt, P.M. Bell, Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes **61**, 167
Lipp, R.W., see Schnedl, W.J. **61**, 77
Liu, G., see Wu, W. **61**, 143
Liu, R., see Hu, Y.M. **61**, 21
Lu, J.-M., see Pan, C.-Y. **61**, 183
Luger, A., see Weitgasser, R. **61**, 13
Luo, B.-Y., see Pan, C.-Y. **61**, 183

Majamaa-Voltti, K., see Vikman, S. **61**, 39
Makino, H., see Ochi, M. **61**, 191
Makino, H., see Ogawa, D. **61**, 137
Makino, I., see Asai, M. **61**, 89
Matsuda, M., see Ogawa, D. **61**, 137
McKillop, A.M., see Lindsay, J.R. **61**, 167
Mensink, M., E. Corpeleijn, E.J.M. Feskens, M. Kruijshoop, W.H.M. Saris, T.W.A. de Bruin, E.E. Blaak, Study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results **61**, 49
Menteş, J., see Afrashi, F. **61**, 7
Mitsuhashi, N., see Miwa, S. **61**, 81
Miwa, S., M. Inouye, C. Ohmura, N. Mitsuhashi, T. Onuma, R. Kawamori, Relationship between carotid atherosclerosis and erythrocyte membrane cholesterol oxidation products in type 2 diabetic patients **61**, 81
Mooney, M.H., see Lindsay, J.R. **61**, 167
Murakami, A., see Ochi, M. **61**, 191
Murase, M., see Ochi, M. **61**, 191

Nakamura, N., G. Hasegawa, H. Obayashi, M. Yamazaki, M. Ogata, K. Nakano, T. Yoshikawa, A. Watanabe, S. Kinoshita, A. Fujinami, M. Ohta, Y. Imamura, T. Ikeda, Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy **61**, 93
Nakanishi, S., K. Yamane, N. Kamei, M. Okubo, N. Kohno, Relationship between development of diabetes and family history by gender in Japanese-Americans **61**, 109
Nakano, K., see Nakamura, N. **61**, 93
Nakao, T., see Shimomura, H. **61**, 103
Nakase, Y., see Shimomura, H. **61**, 103
Nanjo, K., see Shimomura, H. **61**, 103
Nascimento, N.R.F., A. Costa-e-Forti, A.A. Peter, M.C. Fonteles, Free radical scavengers improve the impaired endothelium-dependent responses in aorta and kidneys of diabetic rabbits **61**, 145
Niemelä, K., see Vikman, S. **61**, 39
Niemelä, M., see Vikman, S. **61**, 39
Nishi, M., see Shimomura, H. **61**, 103
Nishimiya, T., see Ochi, M. **61**, 191
Nishizawa, Y., see Yokoyama, H. **61**, 161

Obayashi, H., see Nakamura, N. **61**, 93
Ochi, M., H. Osawa, H. Onuma, A. Murakami, T. Nishimiya, F. Shimada, K. Kato, I. Shimizu, K. Shishino, M. Murase, Y. Fujii, J. Ohashi, H. Makino, The absence of evidence for major effects of the frequent SNP +299G > A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes **61**, 191
Ogata, M., see Nakamura, N. **61**, 93
Ogawa, D., K. Shikata, M. Matsuda, J. Wada, H. Uchida, M. Asada, H. Makino, Pelvic lymphocyst infection associated with maternally inherited diabetes mellitus **61**, 137
O'Harte, F.P.M., see Lindsay, J.R. **61**, 167
Ohashi, J., see Ochi, M. **61**, 191
Ohmura, C., see Miwa, S. **61**, 81
Ohta, M., see Nakamura, N. **61**, 93
Okamoto, K., see Shimomura, H. **61**, 103
Okubo, M., see Nakanishi, S. **61**, 109
Onuma, H., see Ochi, M. **61**, 191
Onuma, T., see Miwa, S. **61**, 81
Osawa, H., see Ochi, M. **61**, 191

Pan, C.-Y., Y. Gao, J.-W. Chen, B.-Y. Luo, Z.-Z. Fu, J.-M. Lu, X.-H. Guo, H. Cheng, Efficacy of acarbose in Chinese subjects with impaired glucose tolerance **61**, 183
Peter, A.A., see Nascimento, N.R.F. **61**, 145
Peuhkurinen, K., see Vikman, S. **61**, 39
Pires, M.L.E., see Halfoun, V.L.R.C. **61**, 155

Rastogi, S., see Gupta, A. **61**, 69
Rijken, M., see El Fakiri, F. **61**, 199
Rodrigues, K.K., see Halfoun, V.L.R.C. **61**, 155
Roisenberg, I., see Santos, K.G. **61**, 133

Salehi, P., see Azizi, F. **61**, 29
Santos, K.G., B. Tschiedel, J. Schneider, K. Souto, I. Roisenberg, Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes **61**, 133
Saris, W.H.M., see Mensink, M. **61**, 49
Sarna, M., see Gupta, A. **61**, 69
Sasaki, H., see Shimomura, H. **61**, 103
Schnedl, W.J., R.W. Lipp, Can human pancreatic β-cells regenerate in vivo? **61**, 77
Schneider, J., see Santos, K.G. **61**, 133
Shikata, K., see Ogawa, D. **61**, 137
Shimada, F., see Ochi, M. **61**, 191
Shimizu, I., see Ochi, M. **61**, 191
Shimomura, H., Y. Nakase, H. Furuta, M. Nishi, T. Nakao, T. Hanabusa, H. Sasaki, K. Okamoto, F. Furukawa, K. Nanjo, A rare case of autoimmune polyglandular syndrome type 3 **61**, 103
Shishino, K., see Ochi, M. **61**, 191
Souto, K., see Santos, K.G. **61**, 133

Tavares, R., see Halfoun, V.L.R.C. **61**, 155
Tian, H.M., see Hu, Y.M. **61**, 21
Tierala, I., see Vikman, S. **61**, 39
Tokunaga, K., see Asakawa, H. **61**, 175
Tschiedel, B., see Santos, K.G. **61**, 133

Uchida, H., see Ogawa, D. **61**, 137
Uebori, S., see Asai, M. **61**, 89

Victer, F., see Halfoun, V.L.R.C. **61**, 155
Vikman, S., K. Niemelä, T. Ilva, K. Majamaa-Voltti, M. Niemelä, K. Peuhkurinen, I. Tierala, K.E.J. Airaksinen, Underuse of evidence-based treatment modalities in diabetic patients with non-ST elevation acute coronary syndrome. A prospective nation wide study on acute coronary syndrome (FINACS) **61**, 39

Wada, J., see Ogawa, D. **61**, 137
Watanabe, A., see Nakamura, N. **61**, 93
Weitgasser, R., M. Lechleitner, A. Luger, A. Klingler, Effects of glimepiride on HbA_{1c} and body weight in Type 2 diabetes: results of a 1.5-year follow-up study **61**, 13
Williams, G.R., see Kolotkin, R.L. **61**, 125
Wu, W., G. Liu, The role of C-reactive protein in type 2 diabetes and its macrovascular complications in Chinese **61**, 143

Yamane, K., see Nakanishi, S. **61**, 109
Yamazaki, M., see Nakamura, N. **61**, 93
Yang, J.-H., see Jang, H.C. **61**, 117
Yim, C.-H., see Jang, H.C. **61**, 117
Yokoyama, H., S. Fukumoto, H. Koyama, M. Emoto, Y. Kitagawa, Y. Nishizawa, Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering **61**, 161
Yoon, H.-K., see Jang, H.C. **61**, 117
Yoshikawa, T., see Nakamura, N. **61**, 93

Zahedi-Asl, S., see Azizi, F. **61**, 29

Available online at www.sciencedirect.com
SCIENCE DIRECT®
Diabetes Research and Clinical Practice 61 (2003) 215–218
DIABETES RESEARCH AND CLINICAL PRACTICE
www.elsevier.com/locate/diabres

Subject index of volume 61

Acarbose; Chinese/Asian population; Impaired glucose tolerance; Metabolic control; Type 2 diabetes prevention **61**, 183

Acute coronary syndrome; Diabetes; Implementation; Guidelines; Treatment **61**, 39

β3-Adrenergic receptor; Resistin; Phosphodiesterase 3B; Lysosomal acid lipase; Single nucleotide polymorphism; Type 2 diabetes; Insulin resistance **61**, 191

Adult; Metabolic syndrome X; Age distribution; Prevalence **61**, 29

Advanced glycation end products; Diabetic retinopathy; Interleukin-6; Vitreous; Retinal Müller cell **61**, 93

Age distribution; Metabolic syndrome X; Adult; Prevalence **61**, 29

A3243G mutation; Pelvic lymphocysts; Infection; Cervical cancer; Mitochondrial DNA **61**, 137

APS; Type 1 DM; Graves' disease; Sjögren's syndrome; Chronic cutaneous lupus erythematosus; Autoimmune neutropenia **61**, 103

Atherosclerosis; Oxidative stress; Cholesterol; Erythrocytes; Gas chromatography–mass spectrometry **61**, 81

Autoimmune neutropenia; APS; Type 1 DM; Graves' disease; Sjögren's syndrome; Chronic cutaneous lupus erythematosus **61**, 103

Blue-on yellow perimetry; Diabetes mellitus; Short-wavelength-sensitive cones; Visual field **61**, 7

Capillaroscopy; Diabetes mellitus; Microcirculation **61**, 155

Carotid intima-media thickness; Paraoxonase; Type 2 diabetes mellitus; Gln–Arg192 polymorphism **61**, 21

Cervical cancer; Pelvic lymphocysts; Infection; Mitochondrial DNA; A3243G mutation **61**, 137

Chinese/Asian population; Acarbose; Impaired glucose tolerance; Metabolic control; Type 2 diabetes prevention **61**, 183

Cholesterol; Atherosclerosis; Oxidative stress; Erythrocytes; Gas chromatography–mass spectrometry **61**, 81

Chronic cutaneous lupus erythematosus; APS; Type 1 DM; Graves' disease; Sjögren's syndrome; Autoimmune neutropenia **61**, 103

Crystalline zinc-insulin; Protamine; Monomerization; Prednisolone; Intradermal test **61**, 161

Dementia; Diabetes; Elderly; Disability; Depression **61**, 59

Depression; Diabetes; Elderly; Disability; Dementia **61**, 59

Diabetes; Acute coronary syndrome; Implementation; Guidelines; Treatment **61**, 39

Diabetes angiopathy; Oxidative damage; Endothelial-dysfunction in the renovascular bed; Diabetic nephropathy **61**, 145

Diabetes; Elderly; Disability; Dementia; Depression **61**, 59

Diabetes; Health care utilisation **61**, 199

Diabetes; Impaired fasting glucose; Insulin resistance syndrome **61**, 69

Diabetes mellitus; Blue-on yellow perimetry; Short-wavelength-sensitive cones; Visual field **61**, 7

Diabetes mellitus; Capillaroscopy; Microcirculation **61**, 155

Diabetes mellitus; O^6-methylguanine; O^6-methylguanine DNA methyltransferase; Leukocyte; HbA_{1c} **61**, 1

Diabetes; Quality of the life; Weight; Impact of Weight on Quality of Life (IWQOL-lite); Health-related quality of life **61**, 125

Diabetic nephropathy; Oxidative damage; Endothelial-dysfunc-

doi:10.1016/S0168-8227(03)00200-6

tion in the renovascular bed; Diabetes angiopathy **61**, 145

Diabetic retinopathy; Advanced glycation end products; Interleukin-6; Vitreous; Retinal Müller cell **61**, 93

Diabetic retinopathy; Type 2 diabetes mellitus; Polymorphisms **61**, 133

Disability; Diabetes; Elderly; Dementia; Depression **61**, 59

Elderly; Diabetes; Disability; Dementia; Depression **61**, 59

Endothelial-dysfunction in the renovascular bed; Oxidative damage; Diabetes angiopathy; Diabetic nephropathy **61**, 145

Erythrocytes; Atherosclerosis; Oxidative stress; Cholesterol; Gas chromatography–mass spectrometry **61**, 81

Family history; Type 2 diabetes; Incidence; Risk factor; Westernized lifestyle **61**, 109

Gas chromatography–mass spectrometry; Atherosclerosis; Oxidative stress; Cholesterol; Erythrocytes **61**, 81

Gastric emptying; Mosapride; Prokinetic drug; Marker method; Gastropathy **61**, 175

Gastropathy; Mosapride; Prokinetic drug; Gastric emptying; Marker method **61**, 175

Gestational diabetes mellitus; Postpartum glucose intolerance; Prevalence; Risk factors **61**, 117

Glimepiride; Type 2 diabetes; Metabolic control; Weight loss; Sulphonylureas **61**, 13

Gln–Arg192 polymorphism; Paraoxonase; Carotid intima-media thickness; Type 2 diabetes mellitus **61**, 21

Glucose tolerance; Nateglinide; Glycated insulin; Type 2 diabetes **61**, 167

Glycated insulin; Nateglinide; Glucose tolerance; Type 2 diabetes **61**, 167

Graves' disease; APS; Type 1 DM; Sjögren's syndrome; Chronic cutaneous lupus erythematosus; Autoimmune neutropenia **61**, 103

Guidelines; Acute coronary syndrome; Diabetes; Implementation; Treatment **61**, 39

HbA_{1c}; O^6-methylguanine; O^6-methylguanine DNA methyltransferase; Leukocyte; Diabetes mellitus **61**, 1

Health care utilisation; Diabetes **61**, 199

Health-related quality of life; Quality of the life; Diabetes; Weight; Impact of Weight on Quality of Life (IWQOL-lite) **61**, 125

Immunological insulin resistance; Insulin lispro; Insulin antibodies **61**, 89

Impact of Weight on Quality of Life (IWQOL-lite); Quality of the life; Diabetes; Weight; Health-related quality of life **61**, 125

Impaired fasting glucose; Diabetes; Insulin resistance syndrome **61**, 69

Impaired glucose tolerance; Acarbose; Chinese/Asian population; Metabolic control; Type 2 diabetes prevention **61**, 183

Impaired glucose tolerance; Lifestyle intervention; Prevalence; Type 2 diabetes; Population screening **61**, 49

Implementation; Acute coronary syndrome; Diabetes; Guidelines; Treatment **61**, 39

Incidence; Type 2 diabetes; Risk factor; Family history; Westernized lifestyle **61**, 109

Infection; Pelvic lymphocysts; Cervical cancer; Mitochondrial DNA; A3243G mutation **61**, 137

Insulin antibodies; Insulin lispro; Immunological insulin resistance **61**, 89

Insulin lispro; Insulin antibodies; Immunological insulin resistance **61**, 89

Insulin resistance; Resistin; Phosphodiesterase 3B; β3-Adrenergic receptor; Lysosomal acid lipase; Single nucleotide polymorphism; Type 2 diabetes **61**, 191

Insulin resistance syndrome; Diabetes; Impaired fasting glucose **61**, 69

Interleukin-6; Diabetic retinopathy; Advanced glycation end products; Vitreous; Retinal Müller cell **61**, 93

Intradermal test; Crystalline zinc-insulin; Protamine; Monomerization; Prednisolone **61**, 161

Leukocyte; O^6-methylguanine; O^6-methylguanine DNA methyltransferase; Diabetes mellitus; HbA_{1c} **61**, 1

Lifestyle intervention; Prevalence; Impaired glucose tolerance; Type 2 diabetes; Population screening **61**, 49

Lysosomal acid lipase; Resistin; Phosphodiesterase 3B; β3-Adrenergic receptor; Single nucleotide polymorphism; Type 2 diabetes; Insulin resistance **61**, 191

Marker method; Mosapride; Prokinetic drug; Gastric emptying; Gastropathy **61**, 175

Metabolic control; Acarbose; Chinese/Asian population; Impaired glucose tolerance; Type 2 diabetes prevention **61**, 183

Metabolic control; Type 2 diabetes; Glimepiride; Weight loss; Sulphonylureas **61**, 13

Metabolic syndrome X; Adult; Age distribution; Prevalence **61**, 29

Microcirculation; Diabetes mellitus; Capillaroscopy **61**, 155

Mitochondrial DNA; Pelvic lymphocysts; Infection; Cervical cancer; A3243G mutation **61**, 137

Monomerization; Crystalline zinc-insulin; Protamine; Prednisolone; Intradermal test **61**, 161

Mosapride; Prokinetic drug; Gastric emptying; Marker method; Gastropathy **61**, 175

Nateglinide; Glycated insulin; Glucose tolerance; Type 2 diabetes **61**, 167

O^6-methylguanine DNA methyltransferase; O^6-methylguanine; Leukocyte; Diabetes mellitus; HbA_{1c} **61**, 1

O^6-methylguanine; O^6-methylguanine DNA methyltransferase; Leukocyte; Diabetes mellitus; HbA_{1c} **61**, 1

Oxidative damage; Endothelial-dysfunction in the renovascular bed; Diabetes angiopathy; Diabetic nephropathy **61**, 145

Oxidative stress; Atherosclerosis; Cholesterol; Erythrocytes; Gas chromatography–mass spectrometry **61**, 81

Paraoxonase; Carotid intima-media thickness; Type 2 diabetes mellitus; Gln–Arg192 polymorphism **61**, 21

Pelvic lymphocysts; Infection; Cervical cancer; Mitochondrial DNA; A3243G mutation **61**, 137

Phosphodiesterase 3B; Resistin; β3-Adrenergic receptor; Lysosomal acid lipase; Single nucleotide polymorphism; Type 2 diabetes; Insulin resistance **61**, 191

Polymorphisms; Diabetic retinopathy; Type 2 diabetes mellitus **61**, 133

Population screening; Lifestyle intervention; Prevalence; Impaired glucose tolerance; Type 2 diabetes **61**, 49

Postpartum glucose intolerance; Gestational diabetes mellitus; Prevalence; Risk factors **61**, 117

Prednisolone; Crystalline zinc-insulin; Protamine; Monomerization; Intradermal test **61**, 161

Prevalence; Gestational diabetes mellitus; Postpartum glucose intolerance; Risk factors **61**, 117

Prevalence; Lifestyle intervention; Impaired glucose tolerance; Type 2 diabetes; Population screening **61**, 49

Prevalence; Metabolic syndrome X; Adult; Age distribution **61**, 29

Prokinetic drug; Mosapride; Gastric emptying; Marker method; Gastropathy **61**, 175

Protamine; Crystalline zinc-insulin; Monomerization; Prednisolone; Intradermal test **61**, 161

Quality of the life; Diabetes; Weight; Impact of Weight on Quality of Life (IWQOL-lite); Health-related quality of life **61**, 125

Resistin; Phosphodiesterase 3B; β3-Adrenergic receptor; Lysosomal acid lipase; Single nucleotide polymorphism; Type 2 diabetes; Insulin resistance **61**, 191

Retinal Müller cell; Diabetic retinopathy; Advanced glycation end products; Interleukin-6; Vitreous **61**, 93

Risk factors; Gestational diabetes mellitus; Postpartum glucose intolerance; Prevalence **61**, 117

Risk factor; Type 2 diabetes; Incidence; Family history; Westernized lifestyle **61**, 109

Short-wavelength-sensitive cones; Blue-on yellow perimetry; Diabetes mellitus; Visual field **61**, 7

Single nucleotide polymorphism; Resistin; Phosphodiesterase 3B; β3-Adrenergic receptor; Lysosomal acid lipase; Type 2 diabetes; Insulin resistance **61**, 191

Sjögren's syndrome; APS; Type 1 DM; Graves' disease; Chronic cutaneous lupus erythematosus; Autoimmune neutropenia **61**, 103

Sulphonylureas; Type 2 diabetes; Glimepiride; Metabolic control; Weight loss **61**, 13

Treatment; Acute coronary syndrome; Diabetes; Implementation; Guidelines **61**, 39

Type 2 diabetes; Glimepiride; Metabolic control; Weight loss; Sulphonylureas **61**, 13

Type 2 diabetes; Incidence; Risk factor; Family history; Westernized lifestyle **61**, 109

Type 2 diabetes; Lifestyle intervention; Prevalence; Impaired glucose tolerance; Population screening **61**, 49

Type 2 diabetes mellitus; Diabetic retinopathy; Polymorphisms **61**, 133

Type 2 diabetes mellitus; Paraoxonase; Carotid intima-media thickness; Gln–Arg192 polymorphism **61**, 21

Type 2 diabetes; Nateglinide; Glycated insulin; Glucose tolerance **61**, 167

Type 2 diabetes prevention; Acarbose; Chinese/Asian population; Impaired glucose tolerance; Metabolic control **61**, 183

Type 2 diabetes; Resistin; Phosphodiesterase 3B; β3-Adrenergic receptor; Lysosomal acid lipase; Single nucleotide polymorphism; Insulin resistance **61**, 191

Type 1 DM; APS; Graves' disease; Sjögren's syndrome; Chronic cutaneous lupus erythematosus; Autoimmune neutropenia **61**, 103

Visual field; Blue-on yellow perimetry; Diabetes mellitus; Short-wavelength-sensitive cones **61**, 7

Vitreous; Diabetic retinopathy; Advanced glycation end products; Interleukin-6; Retinal Müller cell **61**, 93

Weight loss; Type 2 diabetes; Glimepiride; Metabolic control; Sulphonylureas **61**, 13

Weight; Quality of the life; Diabetes; Impact of Weight on Quality of Life (IWQOL-lite); Health-related quality of life **61**, 125

Westernized lifestyle; Type 2 diabetes; Incidence; Risk factor; Family history **61**, 109